The Design and Evaluation of an l-Dopa–Lazabemide Prodrug for the Treatment of Parkinson’s Disease-Reference-Cited by-同舟云学术

The Design and Evaluation of an l-Dopa–Lazabemide Prodrug for the Treatment of Parkinson’s Disease

Published:2017-11-27 Issue:12 Volume:22 Page:2076
ISSN:1420-3049
Container-title:Molecules
language:en
Short-container-title:Molecules

Author:

Hoon Monique,Petzer Jacobus,Viljoen Francois^ORCID,Petzer Anél

Publisher

MDPI AG

Subject

Chemistry (miscellaneous),Analytical Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Molecular Medicine,Drug Discovery,Pharmaceutical Science

Link

http://www.mdpi.com/1420-3049/22/12/2076/pdf

Reference43 articles.

1. Parkinson's Disease

2. Novel Levodopa Formulations for Parkinson’s Disease

3. Novel formulations and modes of delivery of levodopa

4. L-Dopa Prodrugs: An Overview of Trends for Improving Parkinsons Disease Treatment

5. Antiparkinson Prodrugs

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Supplementation of dietary areca nut extract modulates the growth performance, cecal microbiota composition, and immune function in Wenchang chickens;Frontiers in Veterinary Science;2023-12-12

2. Virtual screening of novel mTOR inhibitors for the potential treatment of human colorectal cancer;Bioorganic Chemistry;2023-11

3. The Administration of Levodopa in a Patient With Parkinson’s Disease Using a Novel Maxillofacial Route: A First-in-Human Report;Cureus;2023-10-30

4. ADMINISTRATION OF LEVODOPA IN A PARKINSON’S PATIENT USING A NOVEL ORAL AND MAXILLOFACIAL ROUTE – A FIRST IN HUMAN STUDY;2023-07-16

5. D-DOPA Is a Potent, Orally Bioavailable, Allosteric Inhibitor of Glutamate Carboxypeptidase II;Pharmaceutics;2022-09-23